Contact
Please use this form to send email to PR contact of this press release:
Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
TO:
Please use this form to send email to PR contact of this press release:
Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
TO: